SUBSCRIBE Log In | Sign Up

IPO Profile

Inhibrx, Inc. (INBX)

Offer Price
Offer Size
3-Year Outlook
First Day Turnover


We are a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. We combine a deep understanding of target biology with innovative protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design highly differentiated therapeutic candidates. Central to these efforts is our proprietary single domain antibody, or sdAb, platform.

Our culture empowers data-driven decision making with the aim of eliminating candidate-selection bias in discovery and development. Initially, we are pursuing therapeutic candidates directed to validated targets, where we believe our protein engineering technologies can overcome prior therapeutic limitations. We currently have three oncology programs in human clinical trials as well as a rare disease program for which we expect to initiate a clinical trial in the third quarter of 2019. We also have a preclinical program for which we expect to submit an Investigational New Drug application, or IND, to the United States Food and Drug Administration, or FDA, in 2019 and a preclinical program for which we submitted an IND to the FDA in May 2019. We retain worldwide rights to all of our programs, except for our INBRX-103 therapeutic candidate, for which worldwide rights have been licensed to Celgene Corporation, or Celgene, our INBRX-101 therapeutic candidate, for which we have entered into an option agreement with Chiesi Farmaceutici S.p.A., or Chiesi, for development and commercialization rights outside of the United States and Canada, and certain other therapeutic candidates for which we licensed limited commercial and development rights in certain Asian regions to key collaborators.

We utilize diverse methods of protein engineering to address the specific requirements of complex target and disease biology. We believe our sdAb platform can enable the development of therapeutic candidates with unique mechanisms of action and attributes superior to current monoclonal antibody, or mAb, and fusion protein approaches. sdAbs are small proteins derived from heavy-chain only antibodies naturally produced be the camelid family of animals, which includes camels, alpacas and llamas. sdAbs are highly modular and can be combined to create therapeutic candidates with defined valencies and multiple specificities, enabling enhanced cell signaling and conditional activation. Valency refers to the number of identical antigens bound be a given antibody, and multiple specificities refers to the process of engaging more than one distinct antigen. Importantly, our sdAb-based therapeutic candidates are manufactured by established processes used to produce therapeutic proteins. 

Investors Pre-IPO Holdings (%)
Google Ventures 30
Intel Ventures 20
Patricoff Ventures 5
Kleiner Perkins 18

Deal Highlights

Deal Tracker

Filing Date   18 Aug, 2020
Price Date   19 Aug, 2020
Offer Price $17.00
Offer Size 7M
Look Up Expiry Date   19 Feb, 2021
Earnings Release Date   Nov 1, 2018